Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

Recruiting

• Conditions: Alopecia Areata; Janus Kinase Inhibitors

• Registration Number: NCT06573593
• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-8-25
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Inclusion Criteria:<br><br> - Patients with alopecia areata between 2 to 18 years old<br><br> - Patients diagnosed with alopecia areata according to AA guideline<br><br> - AA Patients treated with JAKi including tofacitinib, baricitinib,<br> ritlecitinib,abrocitinib, upadacitinib and ifidancitinib for more than 3 months<br><br>Exclusion Criteria:<br><br> - Patients had previously received hair implants<br><br> - Other alopecia<br><br> - Other diseases may induce alopecia including psoriasis, lichen planus, et al.<br><br> - Unable to estimate SALT score at baseline or at follow-up<br><br> - Patients are participating in other clinical trials

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean SALT;SALT50;SALT75

Secondary Outcome Measures

Name	Time	Method
Mean SALT;SALT50;SALT75;Safety profile